Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and M

Merck builds case for six-week Keytruda dosing as FDA starts...

BMS' Opdivo/Yervoy combo hits a snag in adjuvant melanoma

UK startup Ervaxx targets ‘dark matter’ of human genome

As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn

Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.

Keytruda gets okay from FDA for adjuvant melanoma

The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes.